Drug intelligence / Profile preview

PTB-03

Development stage: Preclinical
Lead developer: Next Innovative Therapeutics
Administration: Oral

Overview

PTB-03 is a nutraceutical candidate under development by Next Innovative Therapeutics (Nintx) for broad-spectrum digestive support. Developed using Nintx's proprietary GAIApath® and xGIbiomics® platforms, which combine biodiversity, artificial intelligence, and microbiome science, PTB-03 is designed to modulate biological pathways directly and indirectly through gut microbiome modulation. The program is projected to advance in development by 2027.

Beyond the preview

Go deeper on PTB-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTB-03.